Home·Explore by biomarker·RET

RET

Biomarker

RET fusions and mutations are actionable drivers in thyroid and lung cancers. Targeted RET inhibitors are approved for eligible patients.

Approvals
6
Indications
4
Therapies
2
Mapped tests
3

Where this biomarker is used

Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.

Indication-specific approvals

Approvals where RET is defined directly in the indication labeling.

IndicationBiomarker criteriaTherapies
Medullary Thyroid Cancer (MTC)
Solid Tumor · Thyroid
  • RET mutations (SNVs, MNVs, and deletions)
RETEVMO
Non-Small Cell Lung Cancer (NSCLC)
Solid Tumor · Lung
  • fusions
RETEVMOGAVRETO
Thyroid Cancer (TC)
Solid Tumor · Thyroid
  • fusions
RETEVMO
Tumor-agnostic approvals

Approvals defined at the solid tumor level where RET is part of the eligibility criteria.

LevelBiomarker criteriaTherapies
Solid Tumors
  • fusions
RETEVMO

Tests that measure this biomarker

These assays report RET as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.

Test
FoundationOne CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Tissue (FFPE)

Reports RET as part of its biomarker panel.

1 approvalView test profile →
Test
Oncomine Dx Target Test
Life Technologies Corporation
Method
NGS
Specimen
Tissue (FFPE)

Reports RET as part of its biomarker panel.

4 approvalsView test profile →
Test
TruSight Oncology Comprehensive
Illumina, Inc.
Method
NGS
Specimen
Tissue (FFPE)

Reports RET as part of its biomarker panel.

1 approvalView test profile →
This view is scoped to RET. You can also see how it compares with other biomarkers and indications on the Know Your Companions™ map.